Evoclin
Treatment for AcneConnetics' New Drug Application for Actiza Has Been Accepted For Filing by the FDA
PALO ALTO, Calif., March 4, 2004 -- Connetics Corporation (Nasdaq: CNCT), a specialty pharmaceutical company focused on dermatology, today announced that it has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Actiza, as of December 24, 2003. Actiza is an investigational new drug formulation of 1% clindamycin delivered in the Company's proprietary VersaFoam(TM) delivery system, as a potential new topical treatment for acne.
About Connetics
Connetics Corporation is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapeutics
for the dermatology market. The Company's marketed products are
OLUX (clobetasol propionate) Foam, 0.05% and Luxiq (betamethasone
valerate) Foam, 0.12%. Connetics is developing Extina, a foam
formulation of the antifungal drug ketoconazole, Actiza, a foam
formulation of clindamycin for treating acne, and Velac Gel, a
combination of clindamycin and tretinoin for treating acne.
Connetics has branded its innovative foam drug delivery vehicle
VersaFoam(TM). These formulations aim to improve the management of
dermatological diseases and provide significant product
differentiation, and have earned wide acceptance by both physicians
and patients due to their clinical effectiveness, high quality and
cosmetic elegance. For more information about Connetics and its
products, please visit www.connetics.com
Source: Connetics Corporation
Posted: March 2004
Related Articles
- Evoclin Connetics Corporation - Treatment for Acne - October 22, 2004
Evoclin (clindamycin phosphate) FDA Approval History
